Three-Dimensional Imaging of Fibrinogen and Neurovascular Alterations in Alzheimer's Disease.
Level 5 - mechanism / opinion, no new human data
Laboratory technical protocol and method description without clinical trial or comparative epidemiological data.
PubMed 36399266 · doi:10.1007/978-1-0716-2655-9_5
What was done
The authors describe a laboratory protocol combining fibrinogen, amyloid β (Aβ), and vascular immunolabeling with solvent-based tissue clearing (iDISCO) to enable three-dimensional (3D) imaging of large volumes of cleared human brain tissue.
What was found
The abstract describes the protocol's technical capabilities for detecting focal blood-brain barrier vascular abnormalities and mapping the spatial relationships between Aβ plaques and extravasated fibrinogen deposits. No quantitative metrics, sample sizes, or numerical experimental results are provided in the abstract.
Why it matters
Standard 2D histology can miss focal or sparse blood-brain barrier disruption. Volumetric 3D clearing and immunolabeling provides a tool to study spatial neurovascular and neuroimmune interactions in postmortem Alzheimer's disease brain tissue.
Limits
The abstract describes a technical protocol rather than an experimental study with defined control groups, effect sizes, or quantitative outcome measures. Sample size, tissue donor characteristics, clearing artifacts, antibody penetration limits, and reproducibility metrics are not detailed in the abstract.
Cited by
- supports Fibrinogen extravasates and deposits in brain parenchyma in Alzheimer's disease and small vessel disease due to blood-brain barrier breakdown.